Allogene Therapeutics IPO
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR T cell therapies for cancer treatment. The company's approach uses engineered cells from healthy donors rather than patients' own cells, potentially enabling off-the-shelf treatments. Investors track Allogene's clinical progress in the competitive CAR T therapy market.
What We Know
Allogene Therapeutics went public in 2018 through a traditional IPO on NASDAQ. The company raised significant capital in its public offering to advance its allogeneic CAR T platform through clinical development. The stock has experienced volatility common to clinical-stage biotech companies, with performance driven by trial results and regulatory developments. Since going public, Allogene has continued to advance multiple CAR T programs through clinical trials while building out its manufacturing capabilities. The company has also entered into strategic partnerships and licensing agreements to expand its pipeline and technological capabilities.
Frequently Asked Questions
Has Allogene Therapeutics had an IPO?
Yes, Allogene Therapeutics completed its IPO in 2018 and has been publicly traded since then. The company went public to fund its CAR T therapy development.
When is the Allogene Therapeutics IPO date?
Allogene Therapeutics already went public in 2018, so there is no upcoming IPO date. The company has traded publicly for several years.
How can I buy Allogene Therapeutics stock?
You can purchase Allogene Therapeutics stock through any brokerage account under ticker ALLO. The company trades on NASDAQ and is available to public investors.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts